General Information of Drug (ID: DMI7ZK3)

Drug Name
NKTT-120 Drug Info
Synonyms INKT mAb; Natural killer T cell antibody (asthma/COPD/Dermatitis); NKT cell antibody (asthma/COPD/Dermatitis), NKT; Natural killer T cell antibody (asthma/COPD/Dermatitis), NKT Therapeutics
Indication
Disease Entry ICD 11 Status REF
Sickle-cell disorder 3A51 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMI7ZK3

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoglobulin G1k (IgG1k) TTA6ZER NOUNIPROTAC Not Available [2]

References

1 ClinicalTrials.gov (NCT01783691) Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD). U.S. National Institutes of Health.
2 Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42.